These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7721338)

  • 1. An adjuvant formulation based on N-acetylglucosaminyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with dimethyldioctadecylammonium chloride and zinc-L-proline complex as synergists.
    Grubhofer N
    Immunol Lett; 1995 Jan; 44(1):19-24. PubMed ID: 7721338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of immunomodulatory properties of N-acetylmuramyl-L-alanyl-D-isoglutamine and N-acetylglucosaminyl-(beta 1----4)-N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Dozmorov IM; Kuzin II; Lutsan NI; Lutsenko GV; Prokhorova AL; Sapozhnikov AM; Andronova TM; Ivanov VT
    Biomed Sci; 1991; 2(6):651-8. PubMed ID: 1841635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic influences on the adjuvanticity of muramyl dipeptide in vivo.
    Staruch MJ; Wood DD
    J Immunol; 1982 Jan; 128(1):155-60. PubMed ID: 6976368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramylpeptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):19-26. PubMed ID: 3702542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds.
    Azuma I; Sugimura K; Yamawaki M; Uemiya M; Kusumoto S; Okada S; Shiba T; Yamamura Y
    Infect Immun; 1978 Jun; 20(3):600-7. PubMed ID: 97234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preparation and characteristics of monoclonal antibodies to N-acetylglucosaminyl-(beta1-4)-N-acetylmuramoyl-alanyl-D-isoglutamine].
    Mareeva TIu; Kotova OV; Makarov EA; Andronova TM; Nesmeianov VA
    Bioorg Khim; 1993 May; 19(5):555-61. PubMed ID: 8318024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
    Durette PL; Dorn CP; Friedman A; Schlabach A
    J Med Chem; 1982 Sep; 25(9):1028-33. PubMed ID: 7131480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher immunoadjuvant activities of N-acetyl-beta-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine in comparison with N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Tsujimoto M; Kinoshita F; Okunaga T; Kotani S; Kusumoto S; Yamamoto K; Shiba T
    Microbiol Immunol; 1979; 23(9):933-6. PubMed ID: 576117
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Heymer B; Finger H; Wirsing CH
    Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient genetically controlled formation of antibody to a synthetic antigen [poly(LTyr, LGlu)-poly(DLAla)- -poly(LLys)] covalently bound to a synthetic adjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine).
    Mozes E; Sela M; Chedid L
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4933-7. PubMed ID: 6776530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan.
    Chang YH; Pearson CM; Chedid L
    J Exp Med; 1981 Apr; 153(4):1021-6. PubMed ID: 6972989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of immunological adjuvants.
    Warren HS; Vogel FR; Chedid LA
    Annu Rev Immunol; 1986; 4():369-88. PubMed ID: 2871847
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of a synthetic adjuvant (MDP) on qualitative and quantitative changes of serum globulins.
    Leclerc C; Audibert F; Chedid L
    Immunology; 1978 Dec; 35(6):963-70. PubMed ID: 738768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of serum antibody production in mice by oral administration of lipophilic derivatives of muramyl peptides and bacterial lipopolysaccharides with bovine serum albumin.
    Ogawa T; Kotani S; Shimauchi H
    Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):117-25. PubMed ID: 3713372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin.
    Bomford R
    Clin Exp Immunol; 1980 Feb; 39(2):426-34. PubMed ID: 6248282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens.
    Fast DJ; Vosika GJ
    Vaccine; 1997 Nov; 15(16):1748-52. PubMed ID: 9364678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation for hapten help by glucan, muramyl dipeptide, and its L-ala-Glycerol-mycolate derivative.
    Leech SH; Di Luzio NR; Leclerc C
    J Leukoc Biol; 1985 Aug; 38(2):317-25. PubMed ID: 3861748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity.
    Byars NE; Allison AC
    Vaccine; 1987 Sep; 5(3):223-8. PubMed ID: 3499713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Synthesis and protective anti-infective action of anomeric lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine].
    Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
    Bioorg Khim; 2006; 32(4):424-31. PubMed ID: 16909867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.